The UK and US have secured a important bilateral deal that will keep zero duties on UK drug products entering the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has pledged to increase funding on pharmaceuticals through the public health system. This commitment guarantees that tariffs on these key products will stay at nothing for a period of the next three years.
This development comes after recent statements to hike tariffs on patented drug imports, with figures mentioned as high as one hundred percent.
"This agreement with the United Kingdom strengthens the worldwide climate for new treatments and introduces much-needed equity to U.S.–U.K. medicine commerce," a statement said.
Economic Impact
Medicines constitute one of the the United Kingdom's largest exports to the America, which is by far the biggest destination for leading British pharmaceutical firms.
Export figures show that in the year prior to last September, the UK sold medicines valued at over eleven billion pounds to the US. This amount represented a significant portion of all goods exports in that period.
"This deal secures jobs, boosts investment and sets the stage for the UK to emerge as a worldwide center for medical research," the Business and Trade Secretary commented.
Detailed British Pledges
The agreement involves several specific changes from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it deems new treatments to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a goal to increase total health service expenditure on treatments from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to control costs will be restricted at 15%. Previously, repayments were more than 20%.
Broader Context
This agreement follows a long-running dispute between the pharmaceutical industry and the UK government over spending levels and approval rates.
This friction were intensified by arguments that US consumers were paying a premium for the identical medicines than patients in the UK and Europe.
Recently, several significant drug company projects in the UK have been halted or cancelled, while multi-billion-dollar expansions have been directed toward projects in the United States.
One official stated that the NHS needed to invest a greater share on medicines, noting that its spending on drugs had decreased as a percentage of its resources over the last ten years.
